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cost for acute period of MI at hospital was 25,340.00 rubles
($794.36) per patient. There was no signiﬁcant difference
between 3 hospitals. Median total cost for follow-up period in
ﬁrst 6 months after MI was 28,706.63 rubles ($899.89) per
patient for services and drugs mentioned by experts. Median cost
for second 6 months was 11,626.71 rubles ($364.47) per patient;
each 6 months after it required 10,722.73 rubles ($336.14).
CONCLUSION: Costs are relatively low because of rare use of
expensive technologies: only 15% of patients received throm-
bolytical therapy; no coronary artery bypass surgery or stent
implantation were used.
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OBJECTIVES: To estimate the long-term economic and health
impact of managing bradycardia due to sinoatrial node disease
or atrioventricular block with a dual chamber (DDD or DDDR)
vs. single-chamber ventricular pacemaker (VVI or VVIR).
METHODS: A discrete event simulation of 2 identical cohorts
of 1000 patients for 5 years after implantation tracks develop-
ment of post-operative complications, severe pacemaker syn-
drome leading to replacement, atrial ﬁbrillation (which may
become chronic and require anticoagulants), and stroke. Life
expectancy is assumed the same with either device. Risk func-
tions were developed for each device based on two long-term
randomized trials (Canadian Trial of Physiological Pacing,
CTOPP and Mode Selection Trial in Sinus-Node Dysfunction,
MOST). Sensitivity analyses were completed for key input para-
meters. Direct medical costs to the NHS are reported in 2003
British Pounds Sterling (GBP). Beneﬁts were discounted at 1.5%,
and costs 6%. RESULTS: Overall, 29.1% in each cohort died
within 5 years of the implant. Post-operative complications
requiring reoperation increased from 6.4% for VVI(R) to 7.7%
with DDD(R), atrial ﬁbrillation dropped from 22% to 18%;
severe pacemaker symptoms developed in 16.8% with VVI(R)
leading to a wish to switch to DDD(R). Total costs over 5 years
were about 4300 GBP per patient in either cohort. Based on 
100 replications, additional health beneﬁts from DDD(R) are
achieved with a mean net cost of 43 GBP per patient, and 
0.09 QALY gained: a mean cost-effectiveness ratio of 477 GBP
per QALY. In 26% of the replications, however, dual chamber
dominates single chamber. CONCLUSIONS: Whilst implanting
the DDD(R) increases the cost of the initial implantation, this is
predicted to be largely offset by a reduction in long-term 
complications when compared with VVI(R).
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OBJECTIVE: To calculate costs for patients with ischemic stroke
(IS) in common medical practice in Russian Federation.
METHODS. Data on resource use for hospital treatment of
patients with IS were extracted from 70 medical charts at 2 hos-
pitals at Moscow. Data on resource use for out-patient follow-
up for patients after acute myocardial infarction were identiﬁed
according to experts’ opinion. Six experts ﬁlled in the question-
naire for identifying typical follow-up strategy for 1.5 years after
MI. Direct medical costs were calculated on the basis of price-
lists for medical services and median prices for drugs given in a
wholesale pharmaceutical informational bulletin. RESULTS:
Median cost for acute period of IS at hospital was 25,187.00
rubles ($789.56) per patient. There was some difference in costs
between 2 hospitals, but no statistical signiﬁcance was found.
Computer tomography was performed only in 38% patients
(mostly at one hospital). Median total cost for follow-up period
in ﬁrst 6 months after IS was 42,644.50 rubles ($1336.82) per
patient for services and drugs mentioned by experts. Median 
cost for second 6 months was 13,561.08 rubles ($425.11) per
patient; each 6 months after it required 9996.69 rubles
($313.38). CONCLUSIONS: According to experts’ opinion
carotid endarterectomy is performed in no more than 10%
patients after IS.
PCV41
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OBJECTIVES: Pharmaceutical treatment of hypercholes-
terolemia is recommended in individuals with a LDL-cholesterol
level of ≥190mg/dl and 130–189mg/dl plus two other coronary
heart disease risk factors or a coronary heart disease risk >20%
in 10 years. The objective of this study was to assess the 
cost-effectiveness of pharmaceutical treatments of hypercholes-
terolemia in Catalonia, Spain. METHODS: Treatments evalu-
ated included 20, 40, and 80mg/day of lovastatin and
ﬂuvastatin, 10, 20, and 40mg/day of pravastatin, simvastatin
and atorvastatin, 12 and 24g/day of cholestyramine, and 
1.2g/day of gemﬁbrozil. The cost-effectiveness was evaluated
comparing annual treatment costs and the percentage of LDL-
cholesterol reduction. Treatment costs included medication,
medical visits control measures, and treatment of secondary
adverse effects. Wholesale prices in 2002 were used to estimate
medication costs. A metanalysis was carried out to estimate
effectiveness of different treatments, including all published ran-
domized, double blind clinical trials referred on Medline from
1991 to 2002. RESULTS: The annual cost of medication ranged
from 332.98€ for 20mg/day lovastatin to 1105.17€ for 
40mg/day atorvastatin. The percentage of LDL-cholesterol
reduction ranged from 10% for 12g/day cholestyramine to 49%
for 80mg/day atorvastatin. The average cost-effectiveness ratios
in terms of € per one per cent of LDL-cholesterol reduced were
11.22€–22.55€ for atorvastatin, 12.00–21.96€ for simvastatin,
13.87–21.64€ for lovastatin, 15.24–24.69€ for ﬂuvastatin,
20.96–41.77€ for pravastatin, 32.61€ for gemﬁbrozil, and
35.21–45.55€ for cholestyramine. The incremental cost-
effectiveness analysis showed that the more efﬁcient cholesterol-
lowering therapies were 10mg/day atorvastatin, 10mg/day 
simvastatin, 20mg/day lovastatin, 20mg/day ﬂuvastatin, and 20,
40 and 80mg/day atorvastatin. CONCLUSIONS: Efﬁcient statin
therapies detected in this study should be the ﬁrst election cho-
lesterol-lowering drugs used in patients with hypercholes-
terolemia in Catalonia.
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OBJECTIVE: Research has shown that most smokers start
before the age of 18 and after that age the probability to start-
ing smoking decreases steadily. Furthermore, smokers who start
earlier in life are less likely to quit and reducing or delaying 
initiation could have a large impact on public health. In 2002,
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California Assemblyman Paul Koretz (D-West Hollywood) intro-
duced a bill to raise the legal smoking age in the state from 18
to 21. The objective of this research is to estimate the public
health and economic impacts of raising the California legal
smoking age to 21. METHODS: To estimate the health and eco-
nomic impacts, we created a dynamic computer simulation
model. The model simulates the California population as they
age and change their smoking behavior over time. Secondary
data for model parameters were obtained from publicly avail-
able sources. Population health impacts were estimated in terms
of change in smoking prevalence and the change in cumulative
quality-adjusted life-years (QALYs) to the California population
over a 50-year period. Economic impacts were measured in mon-
etary terms for medical cost savings, cost of law enforcement and
cost of checking identiﬁcation. RESULTS: Smoking prevalence
among teens (age 14–17) will drop to 2.4% from current levels
of 13.3%, an 82% reduction. There will be savings of 24 billion
and 1.47 million QALYs will be gained over a period of 50 years
compared to status quo. CONCLUSIONS: This research should
prove useful to California’s policy makers as they contemplate
legislation to raise the state’s legal smoking age.
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OBJECTIVES: Creation of Russian Registry of patients in ACS.
Pharmacoeconomic assessment of costs and consequences of
non-ST segment evaluation ACS (NSTE ACS) by traditional anti-
coagulants and LMWH enoxaparin usage. METHODS: Registry
1 was produced in July 2001 by inclusion of 50 adult hospital
patients in ACS from 59 clinics of Russian cities. A total of 1394
patients were with NSTE ACS, 64% of them received unfrac-
tionated heparin (UFH) and 7.4%—LMWH. Registry 2 was
done in 2003 according the same criteria. A total of 1185
patients from 32 clinics were enrolled. 659 of them were with
NSTE ACS, 19% were treated by UFH, 60%—by enoxaparin.
Pharmacoeconomic analysis “cost—effectiveness” was succeed
as: k = C2 - C1 / E2 - E1. Ñ2 and Ñ1—average value of Cost
per hospital patient in Registry 2 and 1 accordingly (including
costs of treatment and resource utilization). Å2 and Å1—prob-
ability of successful outcomes of the disease in Registry 2 and 1
as well, k—cost per 1% of grow of effectiveness of the treat-
ment. RESULTS: There weren’t statistical discrepancy between
clinical characteristics and duration of hospitalization of patients
into the Registry 1 and 2. A share of more effective treated
patients has been increased in Registry 2 versus Registry 1. Prob-
ability of mortality decreased by 2.3%, reinfarct—by 6.8%,
refractory angina—by 6.3% (g < 0.001). Probability of success-
ful outcomes (E2 - E1) increased by 14.9%. Ñ2 = USD 160.68;
C1 = USD 100.64; E2 = 75.9%; E1 = 61%, K = USD 4.03/ %.
CONCLUSION: Probably the rise of number of successful out-
comes of NSTE ACS in Registry 2 was affected by more active
of LMWH enoxaparin usage. Every percentage of reduction of
serious adverse effects costs extra USD 4.03 but it leads to
increase in the quality of health care and decrease in expendi-
tures on ill effects after discharge from the hospital.
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OBJECTIVES: Vitamin K antagonists (VKAs) have a narrow
therapeutic window and numerous drug and food interactions
and therefore require frequent INR monitoring. This study
aimed to estimate VKA treatment related costs in patients with
chronic nonvalvular atrial ﬁbrillation (NVAF). METHODS:
Data were collected as part of the French arm of ISAM, an Inter-
national Study of Anticoagulation Management. Cost analysis
was from a societal perspective and limited to direct medical
costs. A randomly selected sample of general practitioners (GPs)
and cardiologists (40 GPs, 19 cardiologists) established a regis-
ter of all patients who had received at least 60 consecutive days
of VKA treatment for chronic NVAF in the preceding year. Study
data were obtained from the medical record and by patient 
interview. VKA treatment related costs included INR tests, 
blood sample draws, physician consultations, nurse cost and
VKA related investigations and hospitalisations. Drug costs were
not considered. RESULTS: Of 535 eligible patients, 278 (52%)
were interviewed. A total of 3349 INR tests were collected over
a cumulative follow-up time of 259 years. The mean cost for
INR tests was 69.82€/patient/year; 40.4% of blood samples were
taken at the patient’s home by a nurse, with a mean driving dis-
tance of 4.8km, representing an additional cost of 6.37€ for each
INR taken at home (average 33.25€/patient/year). VKA treat-
ment generated 697 GP and 187 cardiologist face-to-face con-
sultations, at a cost of 70.43€/patient/year. Of 79 hospitalisations
reported during the study period, 14 were judged attributable to
VKAs by an event adjudication committee. These hospitalisa-
tions added a further 153.99€/patient/year. CONCLUSIONS:
The annual cost of ambulatory VKA follow-up was 175€ per
patient. VKA related hospitalisations in this patient sample
added 153.99€, but the exclusion of patients unable to be inter-
viewed may have resulted in underestimation of costs associated
with severe adverse events (stroke, death).
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OBJECTIVES: To perform a retrospective economic evaluation
of an 8-week clinical trial, comparing the efﬁcacy of ﬁxed daily
doses of olmesartan (20mg) versus losartan (50mg), valsartan
(80mg) and irbesartan (150mg) in patients with mild to moder-
ate essential hypertension in Spain. METHODS: A cost-
effectiveness analysis (CEA) was carried out using 2004 drug
acquisition costs for ARA-II evaluated, and proportion of
patients with controlled blood pressure (BP; diastolic BP 
< 90mmHg or a reduction from baseline ≥ 10mmHg) at week
8 as the effectiveness measurement. RESULTS: In this sort-term
study a signiﬁcantly higher reduction of DBP was achieved 
with olmesartan (-11.5mmHg, n = 145) than with losartan 
